Piper Sandler Initiates Coverage On Bio-Techne with Neutral Rating, Announces Price Target of $65
Bio-Techne
Bio-Techne TECH | 0.00 |
Piper Sandler analyst David Westenberg initiates coverage on Bio-Techne (NASDAQ:
TECH) with a Neutral rating and announces Price Target of $65.
